Gout and subsequent increased risk of cardiovascular mortality in non-diabetics aged 50 and above: a population-based cohort study in Taiwan

Victor C Kok, Jorng-Tzong Horng, Hsin-Li Lin, Yu-Ching Chen, Yan-Jun Chen, Kuang Fu Cheng, Victor C Kok, Jorng-Tzong Horng, Hsin-Li Lin, Yu-Ching Chen, Yan-Jun Chen, Kuang Fu Cheng

Abstract

Background: Limited data are available on the risk ratios for fatal cardiovascular disease (CVD) outcome from gout and chronic kidney disease (CKD) in non-diabetic individuals.

Methods: Nationwide population-based retrospective prospective study with a 5-year follow-up to investigate the association between physician-diagnosed gout and CKD in non-diabetics aged 50 and above who had no pre-existing serious CVD and the subsequent risk of death from CVD. Hazard ratios (HR) of CVD mortality were adjusted for gender, age, smoking- and alcoholism-related diagnoses, hypertension, hyperlipidemia, atrial fibrillation and Charlson's comorbidity index score.

Results: A case cohort (n=164,463) having gout and a control cohort (n=3,694,377) having no gout were formed. The prevalence of gout in this study was 4.26% whereas that of gout plus CKD was 8.17%. Male to female ratio among the individuals with gout was 3.2:1. The relative risk (RR) of subsequent cardiovascular mortality between the case and control cohort was 1.71 (95% confidence interval (CI), 1.66-1.75). The presence of CKD in nondiabetic subjects with no gout (control group) has a RR of CVD mortality at 3.05 (95% CI, 2.94-3.15). The presence of gout has protective effect on subjects with CKD with a RR of 1.84 (95% CI, 1.71-1.98). As compared with individuals with no gout, the adjusted HR (aHR) for CVD mortality among the individuals with gout was 1.10 (95% CI 1.07-1.13). In a Cox model, when compared with subjects having neither gout nor CKD, the aHR in subjects with no gout but with CKD is 1.76 (95% CI, 1.70-1.82); in subjects with gout but without CKD, 1.10 (1.07-1.13); interestingly, the aHR is attenuated in subjects with concomitant gout plus CKD which is 1.38 (1.29-1.48).

Conclusions: Among non-diabetic individuals aged 50 years or above who had no preceding serious CVD, those with gout were 1.1 times more likely to die from CVD as were individuals without gout. The presence of gout appears to attenuate the risk of subsequent CV mortality in subjects with CKD. Further studies should focus on finding an explanation for the protective effect of gout on CV mortality in patients with CKD.

Figures

Figure 1
Figure 1
Flowchart illustrating the selection of cases and controls and follow up. Abbreviations: CKD, chronic kidney disease; CVD, cardiovascular disease; NHIRD, National Health Insurance Research Database.

References

    1. Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Eng J Med. 2008;359(17):1811–1821. doi: 10.1056/NEJMra0800885.
    1. Savill P. Gout is an independent risk factor for MI in women. Practitioner. 2010;254(1726):7.
    1. Kuo C-F, See L-C, Luo S-F, Ko Y-S, Lin Y-S, Hwang J-S, Lin C-M, Chen H-W, Yu K-H. Gout: an independent risk factor for all-cause and cardiovascular mortality. Rheumatology. 2010;49(1):141–146. doi: 10.1093/rheumatology/kep364.
    1. De Vera MA, Rahman MM, Bhole V, Kopec JA, Choi HK. Independent impact of gout on the risk of acute myocardial infarction among elderly women: a population-based study. Ann Rheum Dis. 2010;69(6):1162–1164. doi: 10.1136/ard.2009.122770.
    1. Choi HK, Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation. 2007;116(8):894–900. doi: 10.1161/CIRCULATIONAHA.107.703389.
    1. Chien KL, Hsu HC, Sung FC, Su TC, Chen MF, Lee YT. Hyperuricemia as a risk factor on cardiovascular events in Taiwan: The Chin-Shan Community Cardiovascular Cohort Study. Atherosclerosis. 2005;183(1):147–155. doi: 10.1016/j.atherosclerosis.2005.01.018.
    1. Juutilainen A, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Type 2 Diabetes as a “Coronary Heart Disease Equivalent”. Diabetes Care. 2005;28(12):2901–2907. doi: 10.2337/diacare.28.12.2901.
    1. Almdal T, Scharling H, Jensen JS, Vestergaard H. The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death: a population-based study of 13,000 men and women with 20 years of follow-up. Arch Intern Med. 2004;164(13):1422–1426. doi: 10.1001/archinte.164.13.1422.
    1. Lotufo PA, Gaziano JM, Chae CU, Ajani UA, Moreno-John G, Buring JE, Manson JE. Diabetes and All-Cause and Coronary Heart Disease Mortality Among US Male Physicians. Arch Intern Med. 2001;161(2):242–247. doi: 10.1001/archinte.161.2.242.
    1. Hu FB, Stampfer MJ, Solomon CG, Liu S, Willett WC, Speizer FE, Nathan DM, Manson JE. The Impact of Diabetes Mellitus on Mortality From All Causes and Coronary Heart Disease in Women: 20 Years of Follow-up. Arch Intern Med. 2001;161(14):1717–1723. doi: 10.1001/archinte.161.14.1717.
    1. de Jager DJ, Grootendorst DC, Jager KJ, van Dijk PC, Tomas LM, Ansell D, Collart F, Finne P, Heaf JG, De Meester J. et al.Cardiovascular and noncardiovascular mortality among patients starting dialysis. JAMA. 2009;302(16):1782–1789. doi: 10.1001/jama.2009.1488.
    1. Meisinger C, Doring A, Lowel H. Chronic kidney disease and risk of incident myocardial infarction and all-cause and cardiovascular disease mortality in middle-aged men and women from the general population. Eur Heart J. 2006;27(10):1245–1250.
    1. Nitsch D, Lawlor DA, Patel R, Carson C, Ebrahim S. The association of renal impairment with all-cause and cardiovascular disease mortality. Nephrol Dial Transplant. 2010;25(4):1191–1199. doi: 10.1093/ndt/gfp607.
    1. Quinn MP, Cardwell CR, Kee F, Maxwell AP, Savage G, McCarron P, Fogarty DG. The finding of reduced estimated glomerular filtration rate is associated with increased mortality in a large UK population. Nephrol Dial Transplant. 2011;26(3):875–880. doi: 10.1093/ndt/gfq505.
    1. ICD-9-CM. International classification of diseases, 9th revision; clinical modification, 6th edition, Hospital edition edn. Los Angeles: A Practice Management Information Corporation (PMIC), C2005; 2006.
    1. Needham DM, Scales DC, Laupacis A, Pronovost PJ. A systematic review of the Charlson comorbidity index using Canadian administrative databases: a perspective on risk adjustment in critical care research. J Crit Care. 2005;20(1):12–19. doi: 10.1016/j.jcrc.2004.09.007.
    1. Schneeweiss S, Maclure M. Use of comorbidity scores for control of confounding in studies using administrative databases. Int J Epidemiol. 2000;29(5):891–898. doi: 10.1093/ije/29.5.891.
    1. Preis SR, Hwang SJ, Coady S, Pencina MJ, D’Agostino RB Sr, Savage PJ, Levy D, Fox CS. Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham Heart Study, 1950 to 2005. Circulation. 2009;119(13):1728–1735. doi: 10.1161/CIRCULATIONAHA.108.829176.
    1. Krishnan E, Svendsen K, Neaton JD, Grandits G, Kuller LH. Long-term cardiovascular mortality among middle-aged men with gout. Arch Intern Med. 2008;168(10):1104–1110. doi: 10.1001/archinte.168.10.1104.
    1. Teng GG, Ang LW, Saag KG, Yu MC, Yuan JM, Koh WP. Mortality due to coronary heart disease and kidney disease among middle-aged and elderly men and women with gout in the Singapore Chinese Health Study. Ann Rheum Dis. 2012;71(6):924–928. doi: 10.1136/ard.2011.200523.
    1. Goicoechea M, de Vinuesa SG, Verdalles U, Ruiz-Caro C, Ampuero J, Rincon A, Arroyo D, Luno J. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol. 2010;5(8):1388–1393. doi: 10.2215/CJN.01580210.
    1. Kinugasa Y, Ogino K, Furuse Y, Shiomi T, Tsutsui H, Yamamoto T, Igawa O, Hisatome I, Shigemasa C. Allopurinol improves cardiac dysfunction after ischemia-reperfusion via reduction of oxidative stress in isolated perfused rat hearts. Circ J. 2003;67(9):781–787. doi: 10.1253/circj.67.781.
    1. Luk AJ, Levin GP, Moore EE, Zhou XH, Kestenbaum BR, Choi HK. Allopurinol and mortality in hyperuricaemic patients. Rheumatology (Oxford) 2009;48(7):804–806. doi: 10.1093/rheumatology/kep069.
    1. Rhoden E, Teloken C, Lucas M, Rhoden C, Mauri M, Zettler C, Bello-Klein A, Barros E. Protective effect of allopurinol in the renal ischemia–reperfusion in uninephrectomized rats. Gen Pharmacol. 2000;35(4):189–193. doi: 10.1016/S0306-3623(01)00105-7.
    1. Wei L, Mackenzie IS, Chen Y, Struthers AD, MacDonald TM. Impact of allopurinol use on urate concentration and cardiovascular outcome. Br J Clin Pharmacol. 2011;71(4):600–607. doi: 10.1111/j.1365-2125.2010.03887.x.
    1. Yusuf S, Hawken S, Unpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J. et al.Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case–control study. Lancet. 2004;364(9438):937–952. doi: 10.1016/S0140-6736(04)17018-9.
    1. Gami AS, Witt BJ, Howard DE, Erwin PJ, Gami LA, Somers VK, Montori VM. Metabolic Syndrome and Risk of Incident Cardiovascular Events and Death: A Systematic Review and Meta-Analysis of Longitudinal Studies. J Am Coll Cardiol. 2007;49(4):403–414. doi: 10.1016/j.jacc.2006.09.032.
    1. Lakka H-M, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT. The Metabolic Syndrome and Total and Cardiovascular Disease Mortality in Middle-aged Men. JAMA. 2002;288(21):2709–2716. doi: 10.1001/jama.288.21.2709.
    1. Wen CJ, Lee YS, Lin WY, Huang HL, Yao CA, Sung PK, Huang KC. The metabolic syndrome increases cardiovascular mortality in Taiwanese elderly. Eur J Clin Invest. 2008;38(7):469–475. doi: 10.1111/j.1365-2362.2008.01965.x.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅